Startup ValenTx has attracted nearly $10.3 million from 32 investors, according to a filing with the Securities & Exchange Commission. The Maple Grove, Minn. company is developing a removable gastric bypass device as an alternative to Roux-en-Y gastric bypass surgery. It raised $10,271,050 in the round begun July 18, 2018. The ValenTx endoluminal bypass therapy mimics the attributes of […]
Voluntis launches upgraded insulin dosing therapeutic
Voluntis this week launched an upgraded version of Insulia, its digital therapeutic designed to give automated basal insulin dose recommendations and coaching messages for people with Type 2 diabetes. The company touted that its upgraded version of Insulia improves user experience and offers Spanish programming. Get the full story at our sister site, Drug Delivery Business News.
Capillary Biomedical raises $3m to support insulin infusion tech
Capillary Biomedical said today that it raised $2.9 million in a seed funding round to support regulatory filings and the launch of its insulin infusion technology. The company is gearing up for clinical trials to support a 510(k) filing and hopes to bring its SteadiSet infusion set to the market in 2019. Get the full story at our […]
GI Dynamics wins FDA nod for pivotal US EndoBarrier trial
GI Dynamics (ASX:GID) said today it won FDA investigational device exemption approval to launch a pivotal trial of its EndoBarrier device designed for treating patients with type 2 diabetes and obesity, pending Institutional Review Board approval. The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and […]
How Insulet’s CEO plans to create a billion-dollar business
When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a veteran of the medtech industry, saw a path to creating a billion-dollar company and it centered around the concept of making life easier for people with diabetes. “I […]
Medtronic launches engagement program for diabetes patients
Medtronic (NYSE:MDT) said today that it launched its Inner Circle patient engagement program in the U.S. The medtech titan’s program, which is designed for people living with diabetes, uses gamification to motivate and encourage its users to practice behaviors that help them control their blood sugar levels. Get the full story at our sister site, Drug Delivery […]
Valeritas tops sales, earnings estimates in Q2
Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results. The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year. Get the full story […]
Tandem reels in $115m from public offering
Tandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering. The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted. Get the full story at our sister site, Drug […]
Senseonics launches Eversense implantable glucose monitor
Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S. The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey. Get the full story at our sister site, Drug Delivery Business […]
Valeritas lands distro deal in Czech Republic, Slovakia
Valeritas (NSDQ:VLRX) said today that it inked an expanded deal with Med Trust, its distribution partner in Austria and Germany, to promote and sell the V-Go wearable insulin delivery device in the Czech Republic and Slovakia. According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing the device while […]
Tandem prices $100m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 3.5 million shares of common stock at $28.50 apiece. The San Diego, Calif.-based company expects to reel in roughly $100 million in gross proceeds from the offering. Tandem also gave underwriters a 30-day option to buy up to 526,315 additional shares of common stock. Get […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 70
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+